Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis

Inclusion criteria: 1. Age ≥ 15 years 2. TBM defined as "definite", "probable" or "possible" 3. Signed Informed Consent * Definite TBM = at least one of the following criteria: acid-fast bacilli seen in CSF microscopy, positive CSF M. tuberculosis culture, or positive CSF M. tuberculosis commercial nucleic acid amplification test. * Probable TBM = total modified Marais score ≥12 when neuroimaging is available, or ≥10 when neuroimaging is not available (at least 2 points should come from CSF or cerebral imaging criteria). * Possible TBM = total modified Marais 6-11 when neuroimaging is available, or 6-9 when neuroimaging is not available. Exclusion criteria: * \> 5 days of TB treatment * Renal failure (eGFR\<30 ml/min, CKD-EPI formula). * Neutrophil count \< 0.6 x 109/L. * Hemoglobin concentration \< 8 g/dL. * Total bilirubin \> 2.6 times the Upper Limit of Normal * Platelet count \< 50 x 109/L. * ALT \> 5 times the Upper Limit of Normal. * Clinical evidence of liver failure or decompensated cirrhosis. * For women: more than 17 weeks pregnancy or breastfeeding. * For patients without decrease level of consciousness (Glasgow Coma Scale = 15): Peripheral neuropathy scoring Grade 3 or above on the Brief Peripheral Neuropathy Score (BPNS). * Documented M. tuberculosis resistance to rifampicin. * Positive gram-stain, bacterial culture or cryptococcal antigen in the Cerebral Spinal Fluid. * Evidence of active bleeding (hemoptysis, gastrointestinal bleeding, hematuria, intracranial bleeding). * Inability to collect Cerebral Spinal Fluid, except for patients with confirmed tuberculosis (by rapid molecular test or culture) from another biological sample and clinical and/or CT scan evidence of meningitis. * Major surgery within the last two weeks prior to inclusion. * Ongoing chronic aspirin treatment (eg for cardiovascular risk). * Current use of drugs contraindicated with study drugs and that cannot be safely stopped (see Appendix 1: Drugs contra-indicated with study drugs). * In available history from patients: * Evidence of past intracranial bleeding. * Evidence of past of peptic ulceration. * Evidence of recent (\< 3 month) gastrointestinal bleeding. * Known hypersensitivity contraindicating the use of study drugs . * Evidence of porphyria. * Evidence of hyperuricemia or gout. * Any reason which at the discretion of the investigator would compromise safety and cooperation in the trial.